- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| Di | Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery | 65 | Business Wire | MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE... ► Artikel lesen | |
| 16.03. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.12.25 | Apimeds Pharmaceuticals closes $100 million PIPE financing | 2 | Investing.com | ||
| 10.12.25 | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Apimeds merges with MindWave to combine biotech and digital assets | 1 | Investing.com | ||
| 01.12.25 | Apimeds Pharmaceuticals US, Inc. and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE | 613 | Business Wire | Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven... ► Artikel lesen | |
| 18.11.25 | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10.25 | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.05.25 | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 628 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
| 12.05.25 | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 296 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARTELO BIOSCIENCES | 10,510 | +229,47 % | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| QIAGEN | 33,900 | -3,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,250 | +11,58 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,980 | -1,19 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| ONCONETIX | 1,890 | -41,30 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS68237Q2030 Onconetix Inc. 24.03.2026 US68237Q3020 Onconetix Inc. 25.03.2026 Tausch 5:1US98386D3070 XTL Biopharmaceuticals... ► Artikel lesen | |
| ARCELLX | 114,56 | -0,07 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| BIONTECH | 74,50 | -1,84 % | BioNTech Aktie: Panik war gestern! Gründer weg, Kurs im Keller und trotzdem könnte es jetzt ein gutes Investment sein! | © Foto: von Mathurin NAPOLY / matnapo auf Unsplash (Symbolbild)Die Nachricht schlug ein wie eine Bombe: Das Gründerduo Ugur Sahin und Özlem Türeci verlässt BioNTech. Die Reaktion an der Börse war ein... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,85 | -0,74 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,890 | -3,43 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 78,18 | -2,82 % | Kymera Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 38,900 | -0,71 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| CG ONCOLOGY | 64,67 | -2,90 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| STRUCTURE THERAPEUTICS | 45,900 | -0,80 % | Wolfe Research initiates Structure Therapeutics stock rating at Peerperform | ||
| ALUMIS | 24,840 | -5,62 % | Taking a Page From Cancer Drugs, Autoimmune Biotech Alumis Aims for Precision Immunology | ||
| ZENAS BIOPHARMA | 18,275 | -17,53 % | Zenas BioPharma Prices $300M Capital Raise in Dual Offering |
APIMEDS PHARMACEUTICALS US INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,870 Euro und damit +6,55 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.